Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer
The concurrent administration of sacituzumab govitecan and radiotherapy appears well tolerated, with no increased toxicity. This combination may be feasible in metastatic breast cancer patients when clinically indicated. Further studies with larger cohorts are necessary to confirm these findings.
Authors
- Paul Henri Cottu (ORCID: https://orcid.org/0000-0001-6434-3932)
- Pierre Loap (ORCID: https://orcid.org/0000-0001-8863-8110)
- Salma Chabli
- Youlia Kirova (ORCID: https://orcid.org/0000-0002-3527-4082)
Institutions
- Institut Curie (FR)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1097/coc.0000000000001195
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18